Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.
Publication
, Journal Article
Strickler, JH; Hurwitz, HI
Published in: Oncologist
2012
Results of a study, published in this issue of The Oncologist, comparing capecitabine and oxaliplatin plus bevacizumab with the same regimen for only six cycles followed by bevacizumab monotherapy in metastatic colorectal cancer patients are examined.
Duke Scholars
Published In
Oncologist
DOI
EISSN
1549-490X
Publication Date
2012
Volume
17
Issue
1
Start / End Page
9 / 10
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- Male
- Humans
- Female
- Colorectal Neoplasms
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
- Angiogenesis Inhibitors
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Strickler, J. H., & Hurwitz, H. I. (2012). Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability. Oncologist, 17(1), 9–10. https://doi.org/10.1634/theoncologist.2011-0358
Strickler, John H., and Herbert I. Hurwitz. “Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.” Oncologist 17, no. 1 (2012): 9–10. https://doi.org/10.1634/theoncologist.2011-0358.
Strickler JH, Hurwitz HI. Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability. Oncologist. 2012;17(1):9–10.
Strickler, John H., and Herbert I. Hurwitz. “Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.” Oncologist, vol. 17, no. 1, 2012, pp. 9–10. Pubmed, doi:10.1634/theoncologist.2011-0358.
Strickler JH, Hurwitz HI. Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability. Oncologist. 2012;17(1):9–10.
Published In
Oncologist
DOI
EISSN
1549-490X
Publication Date
2012
Volume
17
Issue
1
Start / End Page
9 / 10
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- Male
- Humans
- Female
- Colorectal Neoplasms
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
- Angiogenesis Inhibitors
- 3211 Oncology and carcinogenesis